|
... by the FDA to gain marketing approval of Surfaxin (lucinactant) for the prevention of respiratory distress syndrome in premature infants. Discovery Labs is completing the remaining activities and finalizing the information for its complete response ...
|
|
The FDA has reported that the makers of the cancer drug erlotinib have reported two deaths -- one from hepatorenal syndrome and one from rapidly progressing liver failure -- among patients taking the agent.
|
|
... One patient died from rapidly progressing liver failure and another died from a liver complication called hepatorenal syndrome, the companies said in a letter to doctors. The study was designed for patients with moderate liver impairment and ...
|
|
Audience: Oncological healthcare professionals [Posted 09/23/2008] OSI and Genentech notified healthcare professionals that cases of hepatic failure and hepatorenal syndrome, including fatalities, have been ...
|